

Appl. No. : 09/931,836  
Filed : August 16, 2001



## AMENDMENTS TO THE CLAIMS

1-21 (Cancelled)

22. (Previously Presented) An isolated polypeptide having at least 80% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation;

(b) the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2, lacking its associated signal peptide, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203581, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation.

23. (Previously Presented) The isolated polypeptide of Claim 22 having at least 85% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation;

(b) the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2, lacking its associated signal peptide, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203581, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation.

24. (Previously Presented) The isolated polypeptide of Claim 22 having at least 90% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation;

Appl. No. : 09/931,836  
Filed : August 16, 2001

(b) the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2, lacking its associated signal peptide, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203581, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation.

25. (Previously Presented) The isolated polypeptide of Claim 22 having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation;

(b) the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2, lacking its associated signal peptide, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203581, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation.

26. (Previously Presented) The isolated polypeptide of Claim 22 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation;

(b) the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2, lacking its associated signal peptide, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203581, wherein said isolated polypeptide has the ability to induce chondrocyte redifferentiation.

27-32 (Cancelled)

**Appl. No.** : 09/931,836  
**Filed** : August 16, 2001

33. (Previously Presented) A chimeric polypeptide comprising a polypeptide according to Claim 22 fused to a heterologous polypeptide.

34. (Previously Presented) The chimeric polypeptide of Claim 33, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

35. (New) An isolated polypeptide comprising:

(a) the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2;

(b) the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2, lacking its associated signal peptide; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203581.

36. (New) The isolated polypeptide of Claim 35 comprising the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2.

37. (New) The isolated polypeptide of Claim 35 comprising the amino acid sequence of the polypeptide having the sequence of SEQ ID NO:2, lacking its associated signal peptide.

38. (New) An isolated polypeptide comprising a fragment of a polypeptide having the sequence of SEQ ID NO:2, wherein said fragment comprises amino acids 137-167 of SEQ ID NO:2.

39. (New) The isolated polypeptide of Claim 38, wherein said fragment consists essentially of amino acids 137-167 of SEQ ID NO:2.

40. (New) An isolated polypeptide comprising a fragment of a polypeptide having the sequence of SEQ ID NO:2, wherein said fragment comprises amino acid sequences from SEQ ID NO:2 selected from the group consisting of amino acids 57-91, 60-94, 54-88, 81-114, 78-111, 63-96, 51-84, 45-78, 48-81, 33-66, 66-99, 42-75, 135-169, 202-221, and 235-244.

**Appl. No.** : 09/931,836  
**Filed** : August 16, 2001

**REQUEST FOR CORRECTION OF INVENTORSHIP UNDER 37 C.F.R. § 1.48(b)**  
**DELETION OF INVENTORS**

Applicants submit the following amendment to correct inventorship under 37 C.F.R. § 1.48(b). Accordingly, Applicants request deletion of the following inventors from the above-referenced application:

- |                     |                       |
|---------------------|-----------------------|
| 1. Dan L. Eaton     | 5. James Pan          |
| 2. Audrey Goddard   | 6. Timothy A. Stewart |
| 3. Paul J. Godowski | 7. Colin K. Watanabe  |
| 4. Austin L. Gurney | 8. Zemin Zhang        |

Prosecution of the above-referenced nonprovisional application has resulted in the amendment and cancellation of claims so that fewer than all of the currently named inventors are the actual inventors of the currently claimed subject matter in the application. As required by § 1.48(b), it is hereby acknowledged that the invention(s) of each of the above-named inventors is no longer being claimed in the instant application.

The two remaining inventors are the inventors of the currently claimed subject matter: originally named inventors Luc Desnoyers and William I. Wood.

The processing fee for correction of inventorship in a nonprovisional application is \$130 (37 C.F.R. § 1.17(i)). Enclosed is a check in the amount of \$130.00 for the processing fee. Please charge Deposit Account No. 11-1410 for any fee deficiency.

This statement is made by the attorney signing below, who is a party qualified to do so under 37 C.F.R. § 1.33(b).